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antiretroviral therapy in resource-limited settings:
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Background: A growing proportion of patients on antiretroviral therapy in resource-
limited settings have switched to second-line regimens. We carried out a systematic
review in order to summarize reported rates and reasons for virological failure among
people on second-line therapy in resource-limited settings.
Methods: Two reviewers independently searched four databases and three conference
websites. Full text articles were screened and data extracted using a standardized data
extraction form.
Results: We retrieved 5812 citations, of which 19 studies reporting second-line failure
ratesin2035patientsacrosslow-incomeandmiddle-incomecountrieswereeligiblefor
inclusion. The cumulative pooled proportion of adult patients failing virologically was
21.8, 23.1, 26.7 and 38.0% at 6, 12, 24 and 36 months, respectively. Most studies did
not report adequate information to allow discrimination between drug resistance and
poor adherence as reasons for virological failure, but for those that did poor adherence
appeared to be the main driver of virological failure. Mortality on second-line was low
across all time points.
Conclusion: Rates of virological failure on second-line therapy are high in resource-
limited settings and associated with duration of exposure to previous drug regimens and
poor adherence. The main concern appears to be poor adherence, rather than drug
resistance, from the limited number of studies accessing both factors. Access to
treatment options beyond second-line remains limited and, therefore, a cause for a
concern for those patients in whom drug resistance is the identiﬁed cause of virological
failure.  2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
AIDS 2012, 26:929–938
Keywords: protease inhibitors, second-line failure, viraemia, virological
suppression
Introduction
The rapid scale-up of antiretroviral therapy (ART) in
resource-limited settings over the past decade has resulted
in substantial reductions in morbidity and mortality [1,2]
and increased life expectancy [3] for people living with
HIV/AIDS. Employing a simpliﬁed, standardized pack-
age of care has allowed large numbers of patients to access
life-saving ART in highly under-resourced settings [4].
Particularly, the use of simple, affordable, ﬁxed-dose
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combinationtherapieshassupportedratesof adherenceto
treatment comparable to that seen in developed countries
[5].
A number of patients can be expected to develop drug
resistance to ﬁrst-line regimens, and a growing number of
patientsonARTindeveloping countries haveswitchedto
second-line therapy [6–8]. Limited access to viral load
monitoring and genotyping, and poor availability of
second-line treatment options [9], has meant that failure is
likely underdiagnosed [10], with the consequence that
some patients eligible for second-line therapy are not
switched and many die as a result [11].
For patientsfailingsecond-linetherapy,treatmentoptions
are largely nonexistent. Current WHO guidelines
provide some guidance for treatment in the case of
second-line failure, but these are prefaced with the caveat
that many countries have ﬁnancial constraints that will
limit the adoption of third-line options. For example
South Africa, the best resourced high HIV burden
country in Africa, makes no provision for ART beyond
second-line in its national guidelines [12].
Thus, there is a need to understand the rates and reasons
for virological failure on second-line regimens in
resource-limited settings in order to both limit its
occurrence and forecast the need for treatment options
beyond second-line. In this systematic review, we assess
the frequency and determinants of second-line failure in
resource-limited settings.
Methods
Data sources and searches
We developed a compound search strategy combining
terms for second-line regimens and treatment failure
according to a predeﬁned protocol (http://tinyurl.com/
ctr9rau). The following databases were searched from
inception to July 2011: PubMed, EMBASE, Cochrane
Library and Science Direct. We also searched the websites of
thefollowingconferences:theInternationalAIDSsociety
(IAS), Conference on Retroviruses and Opportunistic
Infections (CROI) and the AIDS Education Global
Information Systems (AEGIS). We additionally searched
the bibliographies of relevant articles and contacted
experts in the ﬁeld to locate additional resources on
ongoing or completed studies. No language or geo-
graphical restriction was applied.
Study selection
We included any study that reported rates of failure
among patients on second-line therapy within clearly
deﬁned cohorts from low-income and middle-income
countries as deﬁned by the World Bank classiﬁcation.
Studies limited to cohorts of only patients failing
second-line treatment were excluded from the main
review, as they could not be used to calculate incidence
estimates. We included randomized trials, nonrando-
mized trials and observational studies, but excluded
nonsystematic observations (case reports or case series
<10 patients). Virological failure was deﬁned according
to the deﬁnitions used in each study, allowing for the
inclusion of studies that performed a single viral load
and studies in which virological failure was conﬁrmed
through two consecutive viral loads. Two reviewers
(O.A., S.M.) independently screened articles by title and
abstract. In case of disagreement or uncertainty, a third
reviewer (N.F.) was consulted. Full text articles were
screened and data extracted using a standardized data
extraction form.
Data extraction and quality assessment
The following data were abstracted: publication status,
year of publication, study design, study location, type of
analysis, age, sample size, type of second-line drugs,
treatment failure deﬁnition, follow-up duration on ﬁrst-
line, follow-up requirements for second-line, follow-up
duration on second-line, baseline genotyping, viral load
monitoring, baseline CD4 cell count, treatment failure
rates (of any kind), genetic mutation, mortality and lost-
to-follow-up at second-line therapy and other failure-
associated factors such as adherence. Where there was
uncertainty about the data, study authors were contacted
for clariﬁcation.
The methodological quality of each study was assessed
independently and in duplicate using a checklist that
assessed the risk of bias across ﬁve different categories
(selection bias, performance bias, detection bias, report-
ing bias and attrition bias) according to the Cochrane
handbook for systematic reviews [13].
Data synthesis and analysis
Point estimates and 95% conﬁdence intervals (95% CIs)
were calculated for the proportion of patients failing
second-line therapy. Where studies reported rates at
different timepoints, results are reported cumulatively.
The variance of the raw proportions was stabilized using
a Freeman–Tukey-type arcsine square-root transform-
ation [14] and estimates were pooled using a DerSi-
monian–Laird random effects model. As pooled
proportions yield high rates of heterogeneity irrespec-
tive of the magnitude of heterogeneity [15], we
estimated the magnitude of heterogeneity using the
t
2-statistic. We explored the potential inﬂuence of
clinical and programmatic covariates identiﬁed through
univariate subgroup analyses to assess the potential
inﬂuence of baseline genotyping and whether the
deﬁnition of virological failure was based on a single test
or two consecutive tests. All P values are two-sided, and
a P value of 0.05 or less was considered to be signiﬁcant.
All analyses were conducted using Stata (version 11;
StataCorp LP, College Station, Texas, USA).
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Role of the funding source
There was no funding source for this study. The
corresponding author had full access to all the data in
the study and had ﬁnal responsibility for the decision to
submit for publication.
Results
Our search strategy identiﬁed a total of 5812 journal
articles and conference papers, of which 5121 were
excluded based on the title either because it was a subject
matter not relevant to our research question; the study
was done in a high-income country; or it was a discussion
paper. After screening full text of published articles and
conference papers with our eligibility criteria, an
additional 496 were excluded (Fig. 1). Of the 195 full
text articles retained, 178 were excluded because they did
notmeet theinclusioncriteria:43werediscussionpapers;
20 included patients on nonprotease-inhibitor based
regimens; 47 studies did not report the outcomes of
interest; 35 did not include data on second-line failure;
and 33 conducted in developed countries. Of ﬁve
additional studies identiﬁed through bibliographic
searches, three were excluded as they reported outcomes
only within a cohort of patients failingtreatment. In total,
19 studies (2035 patients), comprising 13 journal articles
[16–28] and six conference abstracts [29–34], were taken
through for analysis.
The characteristics of studies included in the review are
summarized in Table 1 [16–34]. Studies were published
between2007and2011andcarriedoutinBotswana[29],
South Africa [17,21,23,24,28], Malawi [18], Uganda
[26], Tanzania [31], Cambodia [19,33], Thailand
[20,22,25,32,34] and China [27]. Two studies were
multicentric analyses [16,30].
Most studies (13 studies) deﬁned virological failure using
the WHO deﬁnition of RNA viral load more than
400copies/ml,butonlyaround half ofthesereportedtwo
consecutive measures [17,20,22,26,27,29,30]. Lopinavir-
based second-line regimens were the preferred option in
most studies. The majority (13 studies) performed
baseline genotype testing, but only four studies reported
genotyping among virologically failing patients. Pre-
second-line CD4 cell counts were consistently low, at
around 200cells/ml.
Virological failure on second-line antiretroviral therapy Ajose et al. 931
Potential citations (published
articles and conference
papers) identified from search
strategy (N = 5812)   
Titles retained for further
evaluation (N = 691) 
Articles excluded after screening by full
-text (N = 181):
43 discussion papers
20 non second-line regimens
47 Irrelevant outcome variables
35 First-line failure studies
3 studies reported outcomes only within a 
cohort of patients failing treatment (hand 
search)
33 Study from developed countries
Full-texts articles and
conference abstracts retained
and screened for eligibility 
(N = 195)  
Studies included into the review
(N = 19) (13 journal articles, 6
abstracts)  
Five additional articles
identified by hand 
search 
Fig. 1. Flow diagram of study selection process.Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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The assessment of methodological quality of included
studies is presented in Table 2 [16–34]. The main
limitations of the studies related to the ascertainment of
causes of treatment failure.
Proportion of patients with virological failure on
second-line therapy
Seven studies reported virological failure at 6 months,
with proportions ranging from 8.59 (95% CI 0.36–
26.01%) [32] to 37.34% (95% CI 31.30–43.59%) [29];
the pooled proportion was 21.79% (95% CI 13.25–
30.32%, t
2 105.8) (Fig. 2). Virological failure at 12
months was reported by seven studies and ranged from
11.35 (95% CI 4.89–29.97%) [27] to 39.89% (95% CI
30.27–49.93%) [21],with apooledproportionof23.06%
(95% CI 16.14–29.97%, t
2 69.07). Failure at 24 months
was reported by ﬁve studies in adults and one study in
children. For adults, failure ranged from 8.32 (95% CI
2.93–16.12%) [19] to 41.15% (95% CI 31.54–51.10)
[25], with a pooled proportion of 26.65% (95% CI
14.28–39.02%, t
2 176.9). For children, the proportion
failing second-line was 20.58% (95% CI 10.72–32.64%)
[20]. Finally, three studies reported failure at 36 months
which ranged from 6.4 (95% CI 3.18–10.64%) [16] to
57.32% (42.07–71.88%) [26] with an overall pooled
proportion of 38.02% (95% CI 1.04–74.99%, t
2 100.3).
Insubgroupanalysiscomparingtheproportionofpatients
failing second-line at 6 months, there was no statistically
signiﬁcant difference according to whether baseline
genotyping was assessed or not (P¼0.22), or whether
the deﬁnition of virological failure was based on a single
test or two consecutive tests (P¼0.34). However, the
number of patients contributing to each analysis and the
effect size was small.
Mortality and loss to follow-up
Mortality on second-line regimens was reported by nine
studies. As data were provided for varying treatment
durations, pooled estimates were not calculated. Two
studies reported mortality at 6 months, with mortality
ranging from 2.0 (95% CI 0.5–5.0%) [28] to 6.45% (95%
CI 1.52–14.46%) [31]. Mortality at 12 months was
reported by four studies and ranged from 5.27 (95% CI
3.31–8.38%)[17]to10.49%(95%CI6.68–15.04%)[22].
Twenty-four-month mortality was reported by two
studies, one among adults (4.91%, 95% CI 1.14–
11.10%) [19] and the other in children (6.83%, 95%
CI 1.61–15.28%) [20]. Loss to follow-up of patients on
second-line therapy was reported inconsistently. Two
studies reported losses at six months, ranging from 3.71
(95% CI 2.38–5.32%) [16] to 12.07% (95% CI 7.96–
16.89%) [28]. Three studies reported losses at 12 months
[17,18,22], ranging from 3.41 (95% CI 0.79–7.79%) to
17.04% (95% CI 13.09–21.39%). Two studies reported
losses at 24 months, ranging from 3.49 (95% CI 0.51–
8.97%) to 8.50% (95% CI 2.02–18.83%) [19,26]. Finally,
onestudyreportedthat12.03%ofpatientsonsecond-line
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were lost to follow-up at 60 months (95% CI 8.20–
16.46%) [29].
Determinants of treatment failure
Adherence
Five studies assessed the association between adherence
and second-line failure. A multicentre analysis [16] found
that patients with an adherence index of less than 80%
reportedsigniﬁcantlyhigher treatmentfailurerates(383.5
per 1000person-years) compared with those with an
adherence index of at least 95% (176 per 1000person
years; adjusted incidence rate ratio 3.14; 95% CI 1.67–
5.90; P<0.001). A study from Malawi [18] that deﬁned
pooradherenceas‘ever missingadose’wasreportedtobe
signiﬁcantly associated with failure to achieve HIV-RNA
less than 400copies/ml: after adjusting for potential
confounders, patients rated as poorly adherent were ﬁve
timeslesslikely toachieveviralsuppression(adjustedodds
ratio 5.70; 95% CI 1.16–27.93). A study from Thailand
[25] reported that virological success was greater among
patients who had no documentation of poor adherence
compared with those with documented poor adherence
(hazard ratio 2.94; 95% CI 1.60–5.39; P<0.001). A
study, from South Africa [17], reported that patients
switched to second-line therapy for reasons other than
noncompliance were more likely to achieve second-line
virological success than those shifted for noncompliance
reasons (adjusted hazard ratio 1.83; 95% CI 1.14–2.93); a
second study from South Africa [24] found a non-
signiﬁcant tendency toward a greater risk of viraemia
associated with reported incomplete adherence to
second-line therapy (odds ratio 2.8; 95% CI 0.4–19.6;
P¼0.29).
Drug resistance
Four studies assessed drug resistance patterns among
patients who experienced virological failure [19–21,24].
The most commonly reported resistance mutations were
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for nucleoside reverse transcriptase inhibitors (NRTIs)
(26%, 20 of 78 patients) and non-NRTIs (NNRTIs)
(27%,21of78patients),aswouldbeexpectedfor patients
on second-line therapy. Protease inhibitor resistance
mutations were found in only 18% of patients (14 of 78)
where genotyping was performed. Resistance mutation
associated with M184V was the most prevalent form of
nucleoside reverse transcriptase inhibitor mutation
(16.9%), followed by thymidine analogues (11.7%):
M41L, D67N, K70R, T215F and K219Q. Of the two
studies that detected NNRTI resistance mutations
[19,24], only one reported the speciﬁc mutation. In that
study, K103Nwas themostcommonformof nonnucleo-
side reverse transcriptase inhibitor mutation, observed in
15 patients (19.2%) [24]. Nineteen different mutations
associated with protease inhibitors were also reported
across three studies [20,21,24], with mutations at M36I
and I54V being the most common.
The association between second-line failure and drug
resistance at ﬁrst-line failure was assessed by three studies.
Two of these studies compared resistance mutations at
ﬁrst-line failure in patients who did and did not achieve
virological suppression on second-line therapy [25,27];
these studies found no statistically signiﬁcant difference
between the two groups. In the third study from Uganda,
all 16 patients who underwent resistance testing prior to
second-line ART had at least one mutation conferring
resistance to NNRTI (and 87% of those also had M184V
mutation); virological success (HIV-RNA <400copies/
ml) was achieved at 12 months [26] by all 16 patients.
Discussion
Our analysis found a high proportion of patients on
second-line ARTwere reported to be failing virologically
in resource-limited settings, with most failures occurring
within the ﬁrst 6 months after initiation of second-line
therapy. Failure rates are higher than reported rates of
failure to ﬁrst-line therapy [35] in resource-limited
settings, and reported rates of second-line failure from
developed country settings [36]. The cumulative pooled
proportions reported in this review should be considered
with caution, as there was considerable between-study
variation in the reported estimates and substantial
statistical heterogeneity. Importantly, studies used differ-
ent deﬁnitions of virological failure with over half of
studies included in this review performing a single viral
load. Although we were unable to detect any clear
programme determinants of study heterogeneity, these
sensitivity analyses were limited by the small sample size.
Virological failure on ART can be due to a number of
factors, including baseline drug resistance among patients
prior to starting treatment [37], the evolution of drug
resistance during treatment, duration of time on
treatment and poor adherence to medication. From a
programme perspective, the most important distinction is
between patients who have failed due to drug resistance
(and, therefore, need to switch to a third-line regimen)
and patients who are nonadherent but have not yet
developed drug resistance mutations (and who, therefore,
require adherence support). The majority of studies
included in this review did not provide adequate
information to be able to discriminate between these
two issues. Nevertheless, the fact that for all studies that
measured adherence, poor adherence was a risk factor for
second-line failure, together with the low frequency of
resistance mutations overall, and to protease inhibitors in
particular, suggests thatvirological failure for themajority
of patients is due to suboptimal adherence rather than
resistance development. Protease inhibitors generally
have a high genetic barrier to resistance [38], and studies
that have examined genotypes of patients who had
developed virological failure on second-line therapy
found resistance to lopinavir in only 5.9–11.1% of
patients [39–41].
Adherence to ﬁrst-line therapy was not reported by the
majority of studies, but it is likely that a proportion of
patients failing virologically due to poor adherence to
second-line therapy may also have been poorly adherent
to their initial ﬁrst-line regimen. The higher rate of
failure to second-line therapy compared with ﬁrst-line
therapy may, thus, be partly explained by the fact that a
higher proportion of patients on second-line therapy are
generally poorly adherent. Side-effects are an important
factor associated with poor adherence [42], and
cumulative toxicity associated with nucleosides used in
both ﬁrst-line and second-line regimens may drive poor
adherence in some patients. A number of trials are
underway to improve the evidence base for second-line
therapy and assess the potential for nucleoside-sparing
regimens in treatment-experienced patients that will help
inform the evidence base for future second-line regimens
[43,44]. Another challenge to adherence in resource-
limited settings is the occurrence of antiretroviral drug
shortages. Stock-outs have been reported in several
African countries in recent years and have been associated
with increased treatment interruption and mortality [45].
There are several limitations to note. First, the reporting
of patient and programme variables was inconsistent,
limiting the possibility to conclusively determine factors
driving virological failure. Second, the overall sample size
was small and data were derived from observational
studies which resulted in low statistical precision and a
moderate degree of heterogeneity. We used a random-
effects model which is more appropriate for meta-
analyses in which heterogeneity is anticipated and
explored potential sources of heterogeneity in a series
of subgroup analyses. Third, there may be other
explanations to second-line failures, including drug–
drug interaction (particularly with anti-tuberculosis
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drugs) [46] and drug toxicities that may not have been
adequately considered. Finally, observational studies are
subject to a range of potential biases, as outlined in our
assessment of the methodological quality of studies.
Our study indicates several directions for future research.
Current WHO guidelines recommend that patients
failing virologically be subject to an adherence support
intervention,afterwhichasecondviralloadtestshouldbe
performed prior to decidingon a regimen change. Future
studies should be encouraged to follow these recom-
mendations and report the results of both the ﬁrst and
second viral load, and the type of adherence intervention
carried out, in order to better quantify the proportion of
virological failures due to nonadherence and assess the
effectiveness of adherence interventions. At the same
time, we should not lose sight of the fact that not all
second-linevirologicalfailuresareduetopooradherence,
and access to third-line regimens will likely become a
growing concern for those patients who fail second-
line therapy.
This study, therefore, underscores the need for greater
accesstoroutinevirologicalmonitoring inorder todetect
virological failure and implement more intensive
adherence counselling prior to the development of
resistance mutations. The cost-effectiveness of viral load
in resource-limited settings is still debated [47], but the
beneﬁt of avoiding unnecessary treatment switches and
accumulation of HIV-resistance is increasingly being
acknowledged [48]. Recent costing studies have con-
cluded that when the beneﬁts of guided regimen-
switches are considered, viral load monitoring is found to
be cost-effective and life-saving [49]. Improving the
feasibilityandreducingthecostofviralloadareimportant
policy objectives [50], and a number of strategies have
been proposed to target the use of viral load to help target
its use pending price reductions [51,52].
A number of studies among patients on ﬁrst-line ART
have found that in the majorityof cases, viraemia on ﬁrst-
line therapy can be reversed with adequate adherence
support [53,54]. This, together with algorithms for using
genotyping to conﬁrm drug resistance for cases in which
viraemia is detected on second-line, will help to preserve
the use of second-line drugs which is an important
objective given that therapeutic options beyond second-
line are very expensive and poorly available in resource-
limited settings.
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